Trial Profile
A Phase III Study, Randomized, to Evaluate the Reduction of Chemotherapy Intensity in Association With Nilotinib (Tasigna®) in Philadelphia Chromosome-positive (Ph+) ALL of Young Adults (18-59 Years Old) (GRAAPH-2014)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Feb 2022
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary) ; Asparaginase; Blinatumomab; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Granulocyte colony-stimulating factors; Idarubicin; Imatinib; Mercaptopurine; Methotrexate; Methotrexate; Methylprednisolone acetate; Prednisone; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms GRAALL-2014; GRAAPH2014
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 14 Dec 2021 Results assessing whether the use of nilotinib, a 2nd generation TKI, would allow further decreasing chemotherapy intensity through the omission of high-dose cytarabine (HD-AraC) during consolidation cycles 2 and 4presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology